Screener / SEC EDGAR /CIK 0001001316 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

TG Therapeutics, Inc. TGTX

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. 10-K, Item 1

Headquarters
New York, NY
Next results
around Feb 25, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $616.3M through the costs to a net profit of $447.2M · income statement of the 10-K

20% operating margin
Revenue to Gross profit: $515.6MRevenue to Cost of revenue: $100.7MGross profit to Operating profit: $123.3MGross profit to Operating expenses: $392.2MOperating profit to Net profit: $123.3MOther income to Net profit: $323.9MOperating expenses to R&D: $160.2MOperating expenses to SG&A: $232.0M Revenue: $616.3M REVENUE $616.3M +87% Y/Y Gross profit: $515.6M · 84% margin GROSS PROFIT $515.6M 84% margin Cost of revenue: $100.7M · 16% of revenue COST OF REVENUE $100.7M 16% of revenue Operating profit: $123.3M · 20% margin OPERATING PROFIT $123.3M 20% margin · +194% Y/Y Other income: $323.9M · 53% of revenue OTHER INCOME $323.9M 53% of revenue Operating expenses: $392.2M · 64% of revenue OPERATING EXPENSES $392.2M 64% of revenue Net profit: $447.2M · 73% margin NET PROFIT $447.2M 73% margin · +1812% Y/Y R&D: $160.2M · 26% of revenue R&D $160.2M 26% of revenue SG&A: $232.0M · 38% of revenue SG&A $232.0M 38% of revenue
Gross profit $515.6M 84% margin
Operating profit $123.3M 20% margin · +194% Y/Y
Net profit $447.2M 73% margin · +1812% Y/Y
The full income statement, year by year

TGTX among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 87.3%, above 95% of 154 peers (their median 10.4%) REVENUE GROWTH 87.3% · above 95% Gross margin: 82.7%, above 85% of 107 peers (their median 63.4%) GROSS MARGIN 82.7% · above 85% Operating margin: 21.5%, above 82% of 138 peers (their median 9.8%) OPERATING MARGIN 21.5% · above 82% Net margin: 11.8%, above 65% of 153 peers (their median 6.7%) NET MARGIN 11.8% · above 65% FCF margin: 9.5%, above 47% of 144 peers (their median 10.1%) FCF MARGIN 9.5% · above 47% Return on capital: 39.0%, above 98% of 89 peers (their median 9.0%) RETURN ON CAPITAL 39.0% · above 98%
TGTX Peer median Below the median

What changed

20 new risk paragraphs and 3 accounting facts worth reading about. 10-K filed Feb 27, 2026 against Mar 3, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

3facts worth reading about the other 8 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +136.6% ($129.2M to $305.6M) vs revenue +87.3% ($329.0M to $616.3M), +49.3 pts apart
  • Cash from operations lower than net income
    Cash from operations −$24.8M vs net income $447.2M (FY ending Dec 31, 2025)
  • Critical audit matters changed
    New this year: Realizability of deferred tax assets (“As discussed in Note 9 to the consolidated financial statements, the Company recognizes a valuation allowance for deferred tax assets if, based on review of all available positive and negative evidence, including current and historical results of operations, future income projections, and the overal”). Same as last year: Estimate of certain product revenue reserves
  • Inventory +13.7% ($110.5M to $125.6M) vs revenue +87.3% ($329.0M to $616.3M), -73.6 pts apart
7 more checks with nothing to note
  • Same auditor in both 10-Ks: KPMG LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

20 paragraphs in Risk Factors that were not in the 10-K filed Mar 3, 2025. Quoted as filed.

All 20 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    In addition, recent legislative and regulatory proposals in the United States have included “most favored nation” (“MFN”) or international reference pricing models that would tie reimbursement or net prices for certain drugs to the lowest price available in other countries. Adoption or expansion of MFN or similar reference pricing…
  2. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    We may submit additional information to the FDA which the FDA determines constitutes a major amendment to the application and thereby extends the goal date for determination of approvability of the application;
  3. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    We may be unable to successfully develop, obtain regulatory approval for, or commercialize a subcutaneous formulation of our approved intravenous product, which could limit our ability to expand our market opportunity and patient reach. We are conducting a Phase 3 trial evaluating a subcutaneous (SubQ) formulation of ublituximab, which…
  4. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    In the United States, federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of healthcare and addressing public concern over access and affordability of prescription drugs. The Affordable Care Act (ACA) made significant changes to the U.S. healthcare system, which included…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$2.8M$233.7M$329.0M$616.3M
Net income−$223.8M$12.7M$23.4M$447.2M
Operating cash flow−$176.2M−$31.4M−$40.5M−$24.8M
Free cash flow−$176.2M−$31.4M−$40.6M−$25.0M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$616.3M ▲ 87.3% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

TG Therapeutics, Inc., New York, NY · from the 10-K filed Feb 27, 2026

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S.

Headquarters
New York, NY
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 9, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Mar 3, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TGTX/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.